» Authors » Mariette E Botes

Mariette E Botes

Explore the profile of Mariette E Botes including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 721
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Boender T, Hamers R, Ondoa P, Wellington M, Chimbetete C, Siwale M, et al.
J Infect Dis . 2016 Jul; 214(6):873-83. PMID: 27402780
Background: As antiretroviral therapy (ART) programs in sub-Saharan Africa mature, increasing numbers of persons with human immunodeficiency virus (HIV) infection will experience treatment failure, and require second- or third-line ART....
2.
Boender T, Kityo C, Boerma R, Hamers R, Ondoa P, Wellington M, et al.
J Antimicrob Chemother . 2016 Jun; 71(10):2918-27. PMID: 27342546
Objectives: Limited availability of viral load (VL) monitoring in HIV treatment programmes in sub-Saharan Africa can delay switching to second-line ART, leading to the accumulation of drug resistance mutations (DRMs)....
3.
Boender T, Hoenderboom B, Sigaloff K, Hamers R, Wellington M, Shamu T, et al.
Clin Infect Dis . 2015 Aug; 61(11):1749-58. PMID: 26240203
Background: After the scale-up of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection in Africa, increasing numbers of patients have pretreatment drug resistance. Methods: In a large multicountry cohort...
4.
Hamers R, Zaaijer H, Wallis C, Siwale M, Ive P, Botes M, et al.
J Acquir Immune Defic Syndr . 2013 Jul; 64(2):174-82. PMID: 23892239
Background: This study assessed HIV-hepatitis B virus (HBV) coinfection in southern Africa in terms of prevalence, viral characteristics, occult HBV, and the effect of lamivudine- versus tenofovir-containing first-line combination antiretroviral...
5.
Sigaloff K, Hamers R, Menke J, Labib M, Siwale M, Ive P, et al.
Clin Infect Dis . 2012 May; 54 Suppl 4:S294-9. PMID: 22544190
Human immunodeficiency virus (HIV) RNA testing and HIV drug resistance (HIVDR) testing are not routinely available for therapeutic monitoring of patients receiving antiretroviral therapy (ART) in resource-limited settings. World Health...
6.
Hamers R, Straatsma E, Kityo C, Wallis C, Stevens W, Sigaloff K, et al.
Clin Infect Dis . 2012 May; 54 Suppl 4:S261-5. PMID: 22544185
The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to...
7.
Hamers R, Sigaloff K, Wensing A, Wallis C, Kityo C, Siwale M, et al.
Clin Infect Dis . 2012 Apr; 54(11):1660-9. PMID: 22474222
Background: Human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of antiretroviral therapy (ART). This cohort study examined patterns of drug-resistance mutations (DRMs) in individuals with virological...
8.
Sigaloff K, Hamers R, Wallis C, Kityo C, Siwale M, Ive P, et al.
J Infect Dis . 2012 Mar; 205(11):1739-44. PMID: 22448003
Little is known about the effect of human immunodeficiency virus type 1 (HIV-1) resistance mutations present at time of regimen switch on the response to second-line antiretroviral therapy in Africa....
9.
Hamers R, Schuurman R, Sigaloff K, Wallis C, Kityo C, Siwale M, et al.
Lancet Infect Dis . 2011 Nov; 12(4):307-17. PMID: 22036233
Background: The effect of pretreatment HIV-1 drug resistance on the response to first-line combination antiretroviral therapy (ART) in sub-Saharan Africa has not been assessed. We studied pretreatment drug resistance and...
10.
Hamers R, Wallis C, Kityo C, Siwale M, Mandaliya K, Conradie F, et al.
Lancet Infect Dis . 2011 Aug; 11(10):750-9. PMID: 21802367
Background: There are few data on the epidemiology of primary HIV-1 drug resistance after the roll-out of antiretroviral treatment (ART) in sub-Saharan Africa. We aimed to assess the prevalence of...